Abstract
ROLE OF MXA AND NEUTRALIZING ANTIBODIES IN EARLY RESPONSE TO INTERFERON TREATMENT IN HEPATITIS C EGYPTIAN PATIENTS

Mohammed Ali Saber*, Safia Samir El-Naggar, Moatz Hassen Hassanein and Ahmed Barakat Barakat

ABSTRACT

Pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) treatment does not succeed to attain a sustained virological response (SVR) in about 20-50% of patients with chronic hepatitis C virus (HCV) infection. It has been found that Myxovirus resistance protein A (MxA) gene expression is a reliable and sensitive marker for the presence of exogenous type I interferons (IFNs) during IFN treatment. In addition, considering the involvement of anti-IFN-α binding antibodies (anti-IFN-α2a IgG Abs) and anti-IFN-α neutralizing antibodies (NAbs) on the nonresponse to treatment with PEG-IFN-α2a/RBV, Fifty-two PEG-IFN-α2a/RBV treated patients and sixteen healthy controls (without Hepatitis C) were enrolled in this study. We examined the correlation between MxA gene expression, anti-IFN-α2a IgG Abs and NAbs and the early response to treatment. Quantification of MxA mRNA performed by real-time PCR showed a statistical significant elevation in the mean value of MxA mRNA in early virological responders (EVR) (4.10±1.54) when compared with both controls (3.19±0.89, P ≤ 0.026) and non-early virological responders (non-EVRs) (2.56±1.09, P ≤ 0.001). Anti-IFN-α2a IgG Abs were assessed using indirect ELISA. The percentage of positivity of anti-IFN-α2a IgG antibodies in EVRs was 2/26 (7.7%) and in non-EVRs 4/26 (15.4%). There was no statistical significant difference between the mean values of anti-IFN-α2a IgG antibodies in EVRs (0.46±0.06) and non-EVRs (0.52±0.11), (p ≤ 0.321).). NAbs were distinguished by means of a neutralizing antibody assay that evaluated the neutralizing effects of serum samples against PEG-IFN-α2a. Serum samples were assessed for the presence of NAbs using rabbit polyclonal antihuman IFN-α2a as a positive control. In the 26 EVRs, no NAbs were detected. Of the 26 non-EVRs, two (7.7%) were positive for NAbs (p ≤ 0.149)). This study ensured the importance of the detection of MxA expression as a factor for early assessing the probability of HCV genotype 4 patients to respond to treatment with PEG-IFN-α2a/RBV. Also, it showed that antibody production against IFN-α2a in patients getting treatment for chronic HCV infection is not a significant issue in early prediction of response and is not hindering the response to treatment.

Keywords: anti-interferon-? NAb, chronic hepatitis C, non-response, pegylated interferon-?2a, MxA, indirect ELISA, qRT-PCR and neutralizing antibody assay.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation

  • NEW OCTOBER ISSUE PUBLISHED

    OCTOBER 2020 Issue has been successfully launched on 1 October 2020.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT